Evidence map›Paper›PMID 40952470›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Yongbin Cui, Huadong Wang, Nan Wang, Zhijie Yao, Zhenjiang Li, Qiang Wu, Yong Yin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yongbin Cui *Department of Radiation Oncology Physics and Technology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, No. 440 Jiyan Road, Huaiyin District, Jinan, Shandong Province, China.
Huadong Wang *Department of Radiation Oncology Physics and Technology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, No. 440 Jiyan Road, Huaiyin District, Jinan, Shandong Province, China.
Nan WangDepartment of Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Zhijie YaoDepartment of Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Zhenjiang LiDepartment of Radiation Oncology Physics and Technology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, No. 440 Jiyan Road, Huaiyin District, Jinan, Shandong Province, China.
Qiang WuDepartment of Radiation Oncology Physics and Technology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, No. 440 Jiyan Road, Huaiyin District, Jinan, Shandong Province, China.
Yong YinDepartment of Radiation Oncology Physics and Technology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, No. 440 Jiyan Road, Huaiyin District, Jinan, Shandong Province, China. yinyongsd@126.com.

Funding

Taishan Scholars Project of Shandong Province ts201712098The Key Research and Development Program of Xinjiang Uygur Autonomous Region of China 2022B03019-5
6 · The paper itself

Abstract

objectiveTo investigate the predictive value of pretreatment

methodsThis retrospective study included 19 patients with locally advanced ESCC who underwent nCRT followed by surgery at Shandong Cancer Hospital from March 2022 to May 2023. Pretreatment clinical baseline data,

resultsAmong 19 patients, 11 achieved pCR, and 8 achieved non-pCR status. Univariate and multivariate analyses identified metabolic tumor volume (MTV) (OR = 0.978, p = 0.017) and platelet count (PLT) (OR = 1.003, p = 0.016) as independent predictors of pCR. By fitting a logistic regression model, the two-parameter joint model reached an AUC of 0.909, which was significantly better than the single indicator (MTV, AUC = 0.716; PLT, AUC = 0.761). The nomogram demonstrated that lower MTV (optimal threshold  ≤ 27.47) and higher PLT (optimal threshold  ≥ 330.5) values were associated with a higher likelihood of pCR.

conclusionPretreatment

Indexed as

Biomarkers, TumorChemoradiotherapyEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaNeoadjuvant TherapyPositron Emission Tomography Computed TomographyAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeBiomarkers, Tumor18F-NOTA-FAPI-04 PET/CTEsophageal squamous cell carcinomaMetabolic tumor volumeNeoadjuvant chemoradiotherapyPathological complete response

Identifiers

PMID40952470
PMCPMC12860807

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.